Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Eoghan Mulholland has received the prestigious Lee Placito Research Fellowship in Gastrointestinal Cancer. Eoghan will use this 3-year position to research cell interactions in colorectal cancers.

Eoghan Muholland

Dr Eoghan Mulholland, Postdoctoral Research Scientist in Cancer Genetics at the Wellcome Centre for Human Genetics and member of Somerville College has recently been awarded the Lee Placito Research Fellowship in Gastrointestinal Cancer.

Colorectal cancer (CRC) is currently the 2nd most common cause of cancer death in the UK. To date, research tells us that it isn’t just the genetic defects in the cancer cells that influences how a cancer behaves, but also how the supporting (stromal) and immune cells interact with it. Currently we don’t fully understand how these ‘cell conversations’ initiate and develop but using cutting-edge research methodologies we can have the opportunity to ‘eavesdrop’. Using the Lee Placito Fellowship, Dr Mulholland  will focus in on these cellular exchanges to better understand how cancer cells, stromal cells and immune cells interact with each other across both human tissue and in Genetically Engineered Mouse Models. Through better understanding of this we can then hope to influence how the cells conversation, change the CRC dynamics, and ultimately improve treatment.

On receiving this Fellowship, Dr Mulholland commented:Using the Lee Placito Fellowship, I will focus in on the ‘cell conversations’ between cancer cells, stromal cells and immune cells. Through better understanding of this we can then hope to influence how the cells communicate, change the colorectal cancer dynamics, and ultimately improve treatment.’

Find out more about the Lee Placito Research Fellowship

Similar stories

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.

RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Major new study could help protect millions of people with type 2 diabetes from cardiovascular disease

A new study led by the Nuffield Department of Population Health at the University of Oxford will research whether a daily tablet could help protect the millions of people worldwide with type 2 diabetes from developing cardiovascular disease.

Professor Susan Jebb appointed as Chair of the Food Standards Agency

Susan Jebb, Professor of Diet and Population Health in Oxford University’s Nuffield Department of Primary Care Health Sciences, has been appointed as the new Chair of the Food Standards Agency.